1061

## A NOVEL RESIN GLYCOSIDE, MERREMIN (TUGUAJALAPIN X DIMER), FROM MERREMIA HUNGAIENSIS<sup>1)</sup>

Naoki NODA, a Kyoko TSUJI, a Toshio KAWASAKI, a Kazumoto MIYAHARA, \*, a Hiroshi HANAZONOb and Chon-Ren YANGc

Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-01, Japan, Faculty of Pharmaceutical Sciences, Fukuoka University, b 8-19-1 Nanakuma, Jonanku, Fukuoka 814-01, Japan, and Kunming Institute of Botany, C Academia Sinica, Kunming, Hei-Long-Tan, 650204 Yunnan, China

A novel resin glycoside, merremin (1), has been isolated from the root of Merremia hungaiensis (Convolvulaceae). The structure has been determined to be an ester-type dimer of tuguajalapin X (2) on the basis of chemical and spectral data.

**KEY WORDS** resin glycoside; ester-type dimer; *Merremia hungaiensis*; merremin; Convolvulaceae

In our systematic studies on the characteristic constituents, resin glycosides, of the Convolvulaceae plants, we have isolated a novel resin glycoside named merremin (1) from the roots of Merremia hungaiensis. 1) This paper concerns the structure of 1.

Fraction 3 obtained in the preceding paper<sup>2)</sup> was subjected to HPLC with a Unisil Q PH (10 µm, 16.7 mm x 25 cm, GL Sciences Inc.) using MeOH to give 1 (75 mg).<sup>3)</sup>

The negative HR FAB-MS (m/z 2952.9336 [M-H]<sup>-</sup>) revealed that the molecular formula of 1 is C<sub>156</sub>H<sub>280</sub>O<sub>50</sub>, which corresponds to 2 units of tuguajalapin X (2, C<sub>78</sub>H<sub>140</sub>O<sub>25</sub>)<sup>2)</sup> obtained previously (Fig.1).

Treatment of 1 with 5% KOH followed by methylation with diazomethane gave methyl esters of palmitic acid and operculinic acid A (3), a glycosidic acid obtained from Ipomoea operculata.<sup>4)</sup> In view of the molecular weight of 1 and its components, 1 was considered to have 2 mol of operculinic acid A and 4 mol of palmitic acid.

The <sup>1</sup>H-NMR spectrum of 1 showed the signals due to ten anomeric protons in addition to those assignable to the fatty acid groups; and, when compared with that of 3, remarkable downfield shifts of the signals ascribable to ARha H-2 (1.26 ppm), ARha' H-2 (0.88 ppm), ARha" H-4 (1.55 ppm) AGlc H<sub>2</sub>-6 (0.33 and 0.42 ppm), BRha' H-2 (1.22 ppm) and BRha" H-4 (1.56 ppm) were observed. Furthermore, the diagnostic fragment peaks<sup>5)</sup> in the negative FAB-MS (Fig. 2) suggested that 1 consists of 2 units of 2 and that the carboxyl group of the jalapinolic acid in one unit B is combined with OH of sugar moiety in another unit A.

Mild alkaline hydrolysis of 1 with 28% NH<sub>4</sub>OH and 1,4-dioxane (1:1)<sup>6)</sup> for 13 h at 40°C gave two products, 2 (4.4 %) and 4 (8.0 %),2) together with unreacted 1. The former was identified as 1062 Vol. 43, No. 6

tuguajalapin X (2, unit A) by FAB-MS,  ${}^{1}$ H- and  ${}^{13}$ C-NMR spectral comparison. On the other hand, the  ${}^{1}$ H-NMR spectrum of 4 (m/z: 1493 [M-H] $^{-}$ ) showed equivalent H<sub>2</sub>-2 signals ( $\delta$  2.45, triplet) similar to those of 3, and acylation shifts were seen at Rha' H-2 (1.23 ppm) and Rha" H-4 (1.56 ppm). Therefore, 4 was concluded to be an acylated glycosidic acid as shown in Fig. 1 (unit B).

Taking the hydrolysis product 2 and the down-field shifts at H<sub>2</sub>-6 of AGlc in 1 into account, the full structure of 1 is defined as presented in Fig. 1.

Merremin (1) isolated in the present study is, unlike many resin glycosides so far reported, the first example of an ester-type dimer, which consists of 2 units of the same glycosidic acids partially acylated by fatty acids. This finding may suggest that "rhamnoconvolvulin" from the roots of I.




Fig. 1 Structures of 1, 2 and 4

June 1995 1063

operculata reported by Mannich and Schumann<sup>7)</sup> could be a mixture of oligomers<sup>8)</sup> of resin glycosides acylated by lower organic acids.

m/z 545 m/z 417 m/z 271




Fig. 2 A Part of Negative FAB-MS of 1

## REFERENCES AND NOTES

- 1) Part XXII in the series "Resin Glycosides". For Part XXI see ref. 2).
- 2) Noda N., Tsuji K., Miyahara K., Yang C-L., Chem. Pharm. Bull., 42, 2011 2016 (1994).
- 3) The signals marked with  $^{\#}$  are overlapping.  $\delta$  in ppm from TMS (coupling constants, J (Hz) are in parentheses). 1: mp 104-109°C,  $[\alpha]D^{23}$  -27.7° (c=1.4, CHCl<sub>3</sub>). Negative FAB-MS m/z: 2951 [M-H]<sup>-</sup>, 1493, 1475, 563, 545, 417, 271. Negative HR FAB-MS m/z: 2952.9336 [M-H]-, Calcd. for C<sub>156</sub>H<sub>279</sub>O<sub>50</sub> 2952.9289. <sup>1</sup>H-NMR (pyridine- $d_5$ , 600 MHz)  $\delta$ : 2.26-2.45 (m, 2 x H<sub>2</sub>-2 of Jla), 2.36-2.47 (m, 4 x H<sub>2</sub>-2 of Pal), 0.89 (t, 7.0, 5 x CH<sub>3</sub>), 0.96 (t, 7.0, CH<sub>3</sub>), sugar part, unit A: Fuc, 4.71 (d, 7.5, H-1), 4.14 (dd, 7.5, 9.5, H-2), 4.01<sup>#</sup> (H-3), 3.97<sup>#</sup> (H-4), 3.75 (br q, 6.3, H-5), 1.51 (d, 6.3,  $H_3-6$ ); Rha, 5.48 (d, 1.6, H-1), 5.91 (dd, 1.6, 3.2, H-2), 5.05# (H-3), 4.22 (dd, 9.4, 9.4, H-4), 4.87# (H-5), 1.57 (d, 6.2, H<sub>3</sub>-6); Rha', 6.06 (d, 1.6, H-1), 6.02 (dd, 1.6, 3.1, H-2), 4.74 (dd, 3.1, 8.7, H-3), 4.35# (H-4), 4.38# (H-5), 1.67 (d, 6.3, H<sub>3</sub>-6); Rha", 6.21 (d, 1.2, H-1), 4.88# (H-2), 4.47# (H-3), 5.75 (dd, 9.7, 9.7, H-4),  $4.35^{\#}$  (H-5), 1.42 (d,  $6.3, H_3-6$ ); Glc, 5.04 (d, 7.5, H-1),  $3.97^{\#}$  (H-2),  $4.00^{\#}$  (H-3),  $4.03^{\#}$  (H-4), 3.70(m, H-5), 4.68 (dd, 3.6, 11.7,  $H_a$ -6), 4.84# ( $H_b$ -6), unit B: Fuc, 4.80 (d, 7.9, H-1), 4.49# (H-2), 4.15 (dd, 9.5, 3.4, H-3), 3.95 (br d, 3.4, H-4), 3.81 (br q, 6.5, H-5), 1.53 (d, 6.3, H<sub>3</sub>-6); Rha, 6.23 (br s, H-1), 4.64 (dd, 1.4, 3.2, H-2),  $4.61 \text{ (dd, } 3.2, 9.4, H-3), 4.22 \text{ (dd, } 9.4, 9.4, H-4), } 4.50^{\#} \text{ (H-5), } 1.66 \text{ (d, } 6.3, H_3-6); } \text{Rha', } 5.76 \text{ (br s, H-1), } 6.36 \text{ (dd, } 9.4, 9.4, H-4), } 6.36 \text{ (dd, } 9.4, H-4), } 6.3$ 2.0, 3.2, H-2), 4.77 (dd, 3.2, 9.3, H-3), 4.32 (dd, 9.3, 9.3, H-4), 4.44 (dq, 9.3, 6.3, H-5), 1.65 (d, 6.3, H<sub>3</sub>-6); Rha", 6.20 (br s, H-1), 4.93 (dd, 1.4, 3.2, H-2), 4.53 (dd, 3.2, 9.7, H-3), 5.76<sup>#</sup> (H-4), 4.37<sup>#</sup> (H-5), 1.43 (d, 6.2, H<sub>3</sub>-6); Glc, 5.12 (d, 7.7, H-1),  $3.99^{\#}$  (H-2), 4.10 (dd, 9.0, 9.0, H-3),  $3.99^{\#}$  (H-4), 3.90 (m, H-5),  $4.21^{\#}$  (H<sub>a</sub>-6),  $4.51^{\#}$  (H<sub>b</sub>-6). 4; mp 93-97°C, C<sub>78</sub>H<sub>142</sub>O<sub>26</sub>,  $[\alpha]$ D<sup>24</sup> - 24.4° (c=0.1, CHCl<sub>3</sub>). Negative FAB-MS m/z: 1493 [M-H]<sup>-</sup>, 1255, 1017, 855, 709, 563. <sup>1</sup>H-NMR (pyridine-d<sub>5</sub>, 600 MHz) δ: 2.45 (t, 7.0, H<sub>2</sub>-2 of Jla), 2.37-2.48 (2 x H<sub>2</sub>-2 of Pal), 0.96 (t, 7.0, CH<sub>3</sub>), 0.88 (t, 7.0, 2 x CH<sub>3</sub>), sugar part, Fuc, 4.80 (d, 7.8, H-1), 4.50 (dd, 7.8, 9.5, H-2), 4.15<sup>#</sup> (H-3), 3.61 (br d, 4.4, H-4), 3.82 (br q, 6.5, H-5), 1.50 (d, 6.5, H<sub>3</sub>-6); Rha, 6.24 (br s, H-1), 4.67 (br s, H-2), 4.61 (dd, 3.5, 9.5, H-3), 4.21 (dd, 9.5, 9.5, H-4), 4.90 (dq, 9.5, 6.2, H-5), 1.60 (d, 6.2, H<sub>3</sub>-6); Rha', 5.71 (d, 1.7, H-1), 6.40 (dd, 1.7, 3.4, H-2), 4.82 (dd, 3.4, 9.4, H-3), 4.34 (dd, 9.4, 9.4, H-4), 4.47 (dq, 9.4, 6.1, H-5), 1.67 (d, 6.1, H<sub>3</sub>-6); Rha", 6.24 (br s, H-1), 4.93 (br s, H-2), 4.50<sup>#</sup> (H-3), 5.77 (dd, 9.5, 9.5, H-4), 4.38 (dq, 9.5, 6.2, H-5), 1.40 (d, 6.2, H<sub>3</sub>-6); Glc, 5.17 (d, 7.5, H-1),  $4.02^{\#}$  (H-2),  $4.01^{\#}$  (H-3),  $4.15^{\#}$  (H-4),  $3.98^{\#}$  (H-5), 4.56 (dd, 5.8, 11.0, H<sub>a</sub>-6),  $4.23^{\#}$  $(H_{b}-6).$
- 4) Ono M., Kawasaki T., Miyahara K., Chem. Pharm. Bull., 37, 3209 3213 (1989).
- 5) Noda N., Kobayashi H., Miyahara K., Kawasaki T., Chem. Pharm. Bull., 36, 920 (1988).
- 6) Noda N., Ono M., Miyahara K., Kawasaki T., Tetrahedron, 43, 3889 3902 (1987).
- 7) Mannich C., Schumann P., Arch., Pharm., 276, 211 227 (1938). They proposed the molecular weight as 31018.
- 8) The "rhamnoconvolvulin" fraction obtained by us showed four peaks at m/z 1687, 3333, 4973, 6623 by MALDI TOF-MS (Kubo H., Ono M., Kawasaki T., Miyahara K., Abstracts of Papers (2), The 113th Annual Meeting of Pharmaceutical Society of Japan, Osaka, Mar. 1993, p. 171).